Literature DB >> 23820131

Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.

Chun-Woong Park1, Xiaojian Li, Frederick G Vogt, Don Hayes, Joseph B Zwischenberger, Eun-Seok Park, Heidi M Mansour.   

Abstract

Respirable microparticles/nanoparticles of the antibiotics vancomycin (VCM) and clarithromycin (CLM) were successfully designed and developed by novel organic solution advanced spray drying from methanol solution. Formulation optimization was achieved through statistical experimental design of pump feeding rates of 25% (Low P), 50% (Medium P) and 75% (High P). Systematic and comprehensive physicochemical characterization and imaging were carried out using scanning electron microscopy (SEM), hot-stage microscopy (HSM), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), Karl Fischer titration (KFT), laser size diffraction (LSD), gravimetric vapor sorption (GVS), confocal Raman microscopy (CRM) and spectroscopy for chemical imaging mapping. These novel spray-dried (SD) microparticulate/nanoparticulate dry powders displayed excellent aerosol dispersion performance as dry powder inhalers (DPIs) with high values in emitted dose (ED), respirable fraction (RF), and fine particle fraction (FPF). VCM DPIs displayed better aerosol dispersion performance compared to CLM DPIs which was related to differences in the physicochemical and particle properties of VCM and CLM. In addition, organic solution advanced co-spray drying particle engineering design was employed to successfully produce co-spray-dried (co-SD) multifunctional microparticulate/nanoparticulate aerosol powder formulations of VCM and CLM with the essential lung surfactant phospholipid, dipalmitoylphosphatidylcholine (DPPC), for controlled release pulmonary nanomedicine delivery as inhalable dry powder aerosols. Formulation optimization was achieved through statistical experimental design of molar ratios of co-SD VCM:DPPC and co-SD CLM:DPPC. XRPD and DSC confirmed that the phospholipid bilayer structure in the solid-state was preserved following spray drying. Co-SD VCM:DPPC and co-SD CLM:DPPC dry powder aerosols demonstrated controlled release of antibiotic drug that was fitted to various controlled release mathematical fitting models. The Korsmeyer-Peppas model described the best data fit for all powders suggesting super case-II transport mechanism of controlled release. Excellent aerosol dispersion performance for all co-SD microparticulate/nanoparticulate DPIs was higher than the SD antibiotic drugs suggesting that DPPC acts as an aerosol performance enhancer for these antibiotic aerosol dry powders. Co-SD VCM:DPPC DPIs had higher aerosol dispersion parameters compared to co-SD CLM:DPPC which was related to differences in the physicochemical properties of VCM and CLM.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosol performance enhancer; Antibiotic; Controlled release lung delivery; Dipalmitoylphosphatidylcholine (DPPC); Particle engineering design; Solid-state

Mesh:

Substances:

Year:  2013        PMID: 23820131     DOI: 10.1016/j.ijpharm.2013.06.047

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  22 in total

Review 1.  Spray drying as an advantageous strategy for enhancing pharmaceuticals bioavailability.

Authors:  Alaa Hamed Salama
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

2.  Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.

Authors:  S Sommerfeld Ross; S Gharse; L Sanchez; J Fiegel
Journal:  Int J Pharm       Date:  2017-08-04       Impact factor: 5.875

3.  Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.

Authors:  Nivedita Shetty; Patricia Ahn; Heejun Park; Sonal Bhujbal; Dmitry Zemlyanov; Alex Cavallaro; Sharad Mangal; Jian Li; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2018-08-03       Impact factor: 4.939

4.  Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.

Authors:  Priya Muralidharan; Don Hayes; Stephen M Black; Heidi M Mansour
Journal:  Mol Syst Des Eng       Date:  2016-01-27

5.  High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.

Authors:  Samantha A Meenach; Kimberly W Anderson; J Zach Hilt; Ronald C McGarry; Heidi M Mansour
Journal:  AAPS PharmSciTech       Date:  2014-08-20       Impact factor: 3.246

6.  Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.

Authors:  Frantiescoli Dimer; Cristiane de Souza Carvalho-Wodarz; Jörg Haupenthal; Rolf Hartmann; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2015-06-26       Impact factor: 4.200

7.  Nanoparticle-mediated macrophage targeting-a new inhalation therapy tackling tuberculosis.

Authors:  Shaimaa Makled; Nabila Boraie; Noha Nafee
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

8.  Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery.

Authors:  Alexan I Gomez; Maria F Acosta; Priya Muralidharan; Jason X-J Yuan; Stephen M Black; Don Hayes; Heidi M Mansour
Journal:  Pulm Pharmacol Ther       Date:  2020-10-31       Impact factor: 3.410

9.  Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution.

Authors:  Qian Zhong; Olivia M Merkel; Joshua J Reineke; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2016-05-13       Impact factor: 4.939

10.  Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules.

Authors:  Ernest L Vallorz; Karen Blohm-Mangone; Rick G Schnellmann; Heidi M Mansour
Journal:  AAPS J       Date:  2021-06-24       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.